Lung adenocarcinoma stage III – Diagnostics – Overview of Information and Clinical Research

Diagnosing stage III lung adenocarcinoma involves a careful combination of imaging scans, tissue analysis, and staging procedures to determine the exact extent of the cancer and guide the best treatment approach for each person.

Introduction: Who Should Undergo Diagnostics

Stage III lung adenocarcinoma represents a complex situation where the cancer has spread within the chest but has not yet reached distant organs. Around one-third of people with lung cancer receive their diagnosis at this stage, making it one of the most common presentations of the disease.^[1] Understanding when to seek diagnostic testing is crucial for timely detection and treatment.

People who should consider diagnostic evaluation include those experiencing persistent symptoms that might indicate lung cancer. The most common warning sign is a cough that simply won’t go away, no matter what remedies you try. Other concerning symptoms include unexplained weight loss without trying to lose weight, shortness of breath that gets worse over time, wheezing sounds when breathing, chest pain that doesn’t improve, coughing up blood or rust-colored sputum, and a voice that becomes hoarse without any clear reason.^[7]

Because lung cancer often doesn’t cause noticeable symptoms in its earliest stages, many people don’t realize something is wrong until the disease has progressed. This is why stage III is such a common time for diagnosis—the cancer has grown enough to cause symptoms that prompt someone to see their doctor.^[3] If the cancer has begun spreading beyond the lungs to nearby structures, it might cause additional symptoms depending on which areas are affected. For instance, if it has spread to the bones, you might experience bone pain.

Most people aren’t routinely screened for lung cancer unless they face higher risks, such as being current or former smokers. However, if you’re experiencing any of the symptoms mentioned above, it’s important not to delay seeking medical attention. Early diagnostic evaluation can make a significant difference in treatment options and outcomes.

⚠️ Important

Not everyone with lung cancer experiences symptoms in the early stages. Many people feel completely fine until the disease has progressed significantly. This is why high-risk individuals, particularly those with a history of smoking, should discuss screening options with their healthcare provider even if they feel healthy.

Diagnostic Methods for Stage III Lung Adenocarcinoma

Diagnosing stage III lung adenocarcinoma involves multiple steps and different types of tests. Each test provides specific information that helps doctors understand the size of the tumor, where it’s located, and whether it has spread to nearby tissues or lymph nodes—small bean-shaped organs that are part of the immune system and filter fluids throughout the body.^[7]

Initial Imaging Studies

When someone visits their doctor with symptoms suggesting lung cancer, the diagnostic journey typically begins with a chest X-ray. This is often the first imaging test ordered because it’s widely available, relatively inexpensive, and can quickly show if there’s something unusual in the lungs.^[7] If the X-ray reveals suspicious findings, your doctor will order more detailed tests.

A CT scan (computed tomography scan) is usually the next step. This sophisticated imaging technique uses X-rays and computer processing to create detailed, three-dimensional pictures of the inside of your chest. For lung cancer evaluation, doctors often order a “contrast-enhanced” version, which means you’ll receive an injection of a special dye that helps certain tissues show up more clearly on the images. The CT scan can reveal the size and location of tumors, show whether the cancer has spread to lymph nodes, and identify if it has invaded nearby structures like blood vessels, the chest wall, or other organs in the chest.^[7]

Additional imaging tests help doctors determine if the cancer has spread beyond the chest. A PET scan (positron emission tomography scan) involves injecting a small amount of radioactive sugar into your bloodstream. Cancer cells, which typically consume more sugar than normal cells, appear as bright spots on the scan. This test is particularly useful for detecting cancer that has spread to lymph nodes or other parts of the body that might not be obvious on a CT scan.^[7]

An MRI scan (magnetic resonance imaging) uses powerful magnets and radio waves instead of X-rays to create detailed images. While not always necessary, MRI might be used in specific situations, such as when doctors need to examine whether the cancer has spread to the brain or spinal cord.

Tissue Analysis and Biopsy Procedures

Imaging tests can show suspicious areas, but only examining actual tissue under a microscope can definitively confirm whether cancer is present and identify the specific type. This process is called a biopsy, which means removing a small sample of tissue for laboratory examination.

Several different biopsy techniques might be used depending on where the suspicious tissue is located. A bronchoscopy involves inserting a thin, flexible tube with a tiny camera through your nose or mouth, down your throat, and into your airways. The doctor can look directly at the inside of your airways and take small tissue samples from any abnormal areas. This procedure is done while you’re sedated, so you won’t feel discomfort during the test.

If the suspicious area is located toward the outer edges of the lung where a bronchoscope can’t reach, doctors might perform a needle biopsy guided by CT imaging. During this procedure, you lie on a table while a radiologist uses CT images to guide a thin needle through your chest wall into the tumor. A small tissue sample is withdrawn through the needle for analysis.

In some cases, a mediastinoscopy might be necessary. The mediastinum is the space between your lungs where important structures like your heart, major blood vessels, and multiple lymph node groups are located. During mediastinoscopy, a surgeon makes a small incision at the base of your neck and inserts a thin tube to examine this area and collect tissue samples from lymph nodes. This procedure helps determine whether cancer has spread to lymph nodes in this critical area, which affects staging and treatment planning.^[5]

Laboratory Testing of Tissue Samples

Once tissue samples are collected, pathologists—doctors who specialize in diagnosing disease by examining tissues under microscopes—analyze them carefully. They first confirm whether cancer is present and identify the specific type. Lung adenocarcinoma is one specific subtype of non-small cell lung cancer (NSCLC), which accounts for more than 80% of all lung cancers diagnosed.^[4]

Modern diagnostic testing goes beyond just identifying the cancer type. Laboratory specialists perform additional molecular and genetic testing on the tumor tissue to look for specific mutations—changes in the genetic material of cancer cells. These tests check for alterations in genes like EGFR (epidermal growth factor receptor) and other molecular markers. Identifying these mutations is increasingly important because some targeted therapies work specifically against cancers with particular genetic changes.^[11]

Staging Procedures

Stage III lung cancer is divided into three substages—3A, 3B, and 3C—based on the tumor size, its location, and whether it has spread to lymph nodes and how far those lymph nodes are from the original tumor.^[1] Determining the exact substage requires careful evaluation of all diagnostic information.

The staging system used for NSCLC is called the TNM system. The “T” stands for tumor and describes its size and whether it has grown into nearby structures. The “N” stands for nodes and indicates whether cancer has spread to lymph nodes and which ones. The “M” stands for metastasis and shows whether cancer has spread to distant organs.^[7]

In stage 3A, the cancer might be relatively small (3 cm or less) but has spread to lymph nodes in the mediastinum on the same side as the cancer, or the tumor might be larger (up to 7 cm or more) but hasn’t spread to lymph nodes yet. Stage 3B involves similar-sized tumors but with cancer spread to lymph nodes on the opposite side of the chest or above the collarbone. Stage 3C represents the most advanced form of stage III, with tumors that have spread extensively to lymph nodes on both sides of the chest or in multiple locations.^[1]

Understanding these distinctions matters because treatment approaches can vary depending on the specific substage. Some stage 3A cancers might be considered for surgery after other treatments, while stage 3B and 3C are typically considered unresectable, meaning surgery to remove the cancer isn’t possible or recommended.^[4]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new combinations of existing treatments. For people with stage III lung adenocarcinoma, participating in a clinical trial might provide access to innovative therapies not yet widely available. However, joining a trial requires meeting specific eligibility criteria, and diagnostic tests play a crucial role in determining whether someone qualifies.

Every clinical trial has what are called inclusion criteria—the characteristics people must have to participate—and exclusion criteria—factors that would prevent someone from joining. Diagnostic tests provide the objective evidence needed to determine whether someone meets these requirements.

Accurate staging is one of the most fundamental requirements for trial participation. Trials specifically designed for stage III NSCLC will only enroll patients whose diagnostic workup confirms they have stage III disease and not an earlier or more advanced stage. This typically requires complete imaging studies including CT scans and often PET scans to document the extent of disease.^[5]

Many modern clinical trials, particularly those testing targeted therapies or immunotherapies, require specific molecular testing results. For example, a trial testing a new drug designed for tumors with EGFR mutations will only accept patients whose biopsy tissue testing showed this specific mutation. Similarly, some immunotherapy trials require testing for biomarkers like PD-L1 expression levels—a protein found on some cancer cells that affects how the immune system responds to them.^[11]

Blood tests are another important component of trial qualification. Researchers need to verify that potential participants have adequate organ function to safely tolerate experimental treatments. Standard blood work checks liver function, kidney function, blood cell counts, and other markers of overall health. These tests must show that organs are working well enough to process the investigational drugs.

Some trials require specialized tests not routinely performed in standard care. For instance, a trial might require genetic sequencing of tumor tissue to identify a broad panel of mutations, or specific imaging techniques to measure tumor characteristics in particular ways. Trial sponsors typically arrange and often pay for these specialized tests if they’re needed solely for research purposes.

Performance status assessment is another critical element. Doctors use standardized scales to evaluate how cancer affects daily living activities. These assessments help determine whether someone is healthy enough to handle experimental treatments. While not a “diagnostic test” in the traditional sense, these functional assessments are documented evaluations that factor into trial eligibility.

⚠️ Important

Clinical trial participation isn’t right for everyone, but it can be an important option worth discussing with your healthcare team. The diagnostic tests required for trial enrollment often provide additional valuable information about your cancer that can inform treatment decisions even if you ultimately don’t join the study.

It’s worth noting that the specific diagnostic requirements vary significantly between different clinical trials. Some trials have very restrictive criteria and require extensive testing, while others have broader eligibility requirements. If you’re interested in clinical trials, your healthcare team can help identify studies that match your situation and guide you through the necessary diagnostic evaluations.

Prognosis and Survival Rate

Prognosis

The outlook for people with stage III lung adenocarcinoma depends on multiple factors that influence how the disease might progress and respond to treatment. The specific substage (3A, 3B, or 3C) plays an important role—generally, stage 3A has a better outlook than stage 3B or 3C because the cancer hasn’t spread as extensively. The size and location of the tumor matter as well, along with whether the cancer can be removed through surgery after initial treatments.^[1]

A person’s age and overall health significantly affect prognosis. Younger individuals and those in otherwise good health typically tolerate treatments better and may have improved outcomes. How well someone can perform daily activities—what doctors call “performance status”—also influences the outlook. People who can maintain relatively normal activity levels often respond better to treatment than those whose cancer has already significantly limited their function.^[3]

The specific characteristics of the cancer cells themselves matter too. Certain genetic mutations in the tumor, such as EGFR mutations, may respond particularly well to targeted therapies, potentially improving outcomes. The presence or absence of certain biomarkers can indicate which treatments are most likely to work. Additionally, how the cancer responds to initial treatment—whether it shrinks, stays stable, or continues growing—provides important information about the likely course of the disease.^[11]

Stage III non-small cell lung cancer is sometimes called “locally advanced cancer” because while it has spread beyond the original lung, it hasn’t reached distant organs. This makes it potentially treatable with aggressive, multimodal approaches that combine different types of therapy. Some people with stage III disease can achieve long-term survival, particularly when the cancer responds well to treatment.^[6]

Survival rate

Survival statistics provide a general picture of outcomes for groups of people, but they cannot predict what will happen for any individual person. According to data from England covering people diagnosed between 2016 and 2020, around 15 out of 100 people (approximately 15%) with stage 3 lung cancer survived for 5 years or more after diagnosis.^[19] These figures represent all types of stage 3 lung cancer combined and don’t account for differences in age or specific substages.

It’s important to understand that survival rates are based on people who were diagnosed several years ago. Treatment for lung cancer has advanced considerably in recent years, particularly with the introduction of immunotherapy and targeted therapies. People diagnosed today may have access to treatments that weren’t available when these statistics were compiled, potentially leading to improved outcomes.^[5]

Roughly 20% of people with non-small cell lung cancer receive their diagnosis at stage 3, making it one of the most common stages at diagnosis. While stage 3 is more challenging to treat than earlier stages, it’s still considered potentially curable in some cases, particularly in the 3A substage where surgery might be an option after chemotherapy and radiation therapy.^[6]

Survival also varies significantly based on whether someone receives treatment and which treatments are used. People who are healthy enough to tolerate aggressive, multimodal treatment approaches generally have better outcomes than those who cannot undergo intensive therapy due to other health conditions or advanced age. The specific treatment plan developed by your multidisciplinary medical team—considering all aspects of your health and your cancer’s characteristics—offers the best approach for your individual situation.

Remember that statistics describe averages across large groups of people. They cannot account for individual variations in cancer biology, overall health, response to treatment, and many other factors that make each person’s experience unique. Many people exceed average survival estimates, while others face greater challenges. Your healthcare team can provide more personalized information based on your specific circumstances.

#1 Clinical Trials Search in Europe